Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Brian Bergmark Added: 2 weeks ago
EuroPCR 2026 – Dr Brian Bergmark (Brigham and Women's Hospital, Boston, MA, US) joins us to discuss findings from the VESALIUS-CV trial, examining the effect of evolocumab in patients who have undergone coronary stenting but have no prior myocardial infarction or stroke.VESALIUS-CV is a double-blind, randomised, placebo-controlled, multicentre phase 3 trial enrolling 12,301 high-cardiovascular… View more
Added: 4 months ago Source:  Radcliffe Vascular
The optimal management for asymptomatic carotid stenosis has been a subject of debate, particularly with advancements in medical therapy. New findings from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) provide clarity, suggesting a benefit for carotid-artery stenting when added to intensive medical management.¹MethodologyCREST-2 involved… View more
Added: 4 months ago Source:  Radcliffe Vascular
The optimal management for patients with high-grade asymptomatic carotid stenosis remains a key clinical question, particularly with advancements in medical therapy and revascularisation techniques. The CREST-2 trials were designed to assess whether adding revascularisation to intensive medical management provides a greater benefit than intensive medical management alone in this patient… View more
Author(s): Tiziana Claudia Aranzulla Added: 9 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more
Added: 11 months ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryThe selection of drug-eluting stents (DES) for percutaneous coronary intervention (PCI) involves balancing efficacy against safety. The SORT OUT XI randomised trial aimed to compare a newer-generation biolimus-eluting stent with a contemporary dual-therapy sirolimus-eluting stent in a real-world patient population, providing crucial head-to-head evidence.¹SORT OUT XI was a… View more
Author(s): Marianne Brodmann Added: 8 months ago
CIRSE Congress 2025 - 24-month results show the Biotronik Dynetic-35 cobalt chromium balloon-expandable stent was safe and effective in iliac arteries.Prof Marianne Brodmann (Medical University of Graz, Graz, AT) joins us to discuss 24-month findings from BIONETIC-I (NCT04830228). The prospective, international, multi-center, single-arm study aimed to investigate the safety and effectiveness of… View more